Melanoma risk prediction of a validated genetic signature compared to the AJCC online predictor - 09/05/15
Laura Ferris, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States; Robert Cook, PhD, Castle Biosciences, Inc, Friendswood, TX, United States; Jeff Wilkinson, PhD, St Joseph’s Hospital and Medical Center, Phoenix, AZ, United States; Natalie Lassen, RN, Castle Biosciences, Phoenix, AZ, United States; Clare Johnson, RN, Castle Biosciences, Phoenix, AZ, United States; Kristen Oelschlager, RN, Castle Biosciences, Phoenix, AZ, United States; John Stone, PhD, St Joseph’s Hospital and Medical Center, Phoenix, AZ, United States; Derek Maetzold, Castle Biosciences, Friendswood, TX, United States; Maria Russell, MD, Winship Cancer Institute of Emory University, Atlanta, GA, United States; Keith Delman, MD, Winship Cancer Institute of Emory University, Atlanta, GA, United States; David Lawson, MD, Winship Cancer Institute of Emory University, Atlanta, GA, United States; Pedram Gerami, MD, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
Le texte complet de cet article est disponible en PDF.| This study was funded by Castle Biosciences. |
Vol 72 - N° 5S1
P. AB172 - mai 2015 Retour au numéro
Article précédent
- Melanoma gene expression in adhesive-tape sampled lesions is similar in primary tumors and patient-derived xenografts
- MeTC7, a novel vitamin D receptor (VDR) antagonist, induces cytotoxicity in metastatic melanoma cell lines and inhibits importin-mediated VDR nuclear transport and signaling
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?